{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-118344","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-10-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.967767+00:00","generated_at":"2026-05-30T09:23:46.737204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biomea Fusion reports Q3 net loss of $32.8M; FDA lifts clinical hold on diabetes trials","bullets":["Cash and cash equivalents $88.3M as of Sep 30, 2024, down from $177.2M at Dec 31, 2023.","Net loss $32.8M for Q3 2024 vs $28.4M same period 2023; includes $4.7M stock-based comp.","FDA lifted clinical hold on COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) trials.","Topline Week 26 data for both trials expected in December 2024.","Announced third clinical candidate BMF-650 (oral GLP-1 RA); preclinical data to be shared Oct 30."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-118344","json":"https://secwatch.observer/filing/0000950170-24-118344.json","markdown":"https://secwatch.observer/filing/0000950170-24-118344.md","text":"https://secwatch.observer/filing/0000950170-24-118344.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024118344/0000950170-24-118344-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000095017024118344/bmea-20241029.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:23:46.737204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}